The Current State of Timely Results Reporting Among Hypertension Trials on ClinicalTrials.gov: A Cross-Sectional Meta-Research Analysis
This cross-sectional meta-research analysis of 5,851 hypertension trials on ClinicalTrials.gov reveals that timely results reporting remains uncommon (9.1%), with compliance significantly higher only among studies meeting observable regulatory obligations, particularly those involving US sites.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Imagine the world of medical research as a massive, bustling library where scientists write books about new ways to treat diseases. For a long time, there was a frustrating problem: authors could write a book, finish it, and then decide to hide it in a back room if the story didn't turn out the way they hoped. If they only showed the library the books with happy endings, the librarians (doctors) would think the story always has a happy ending, even when it doesn't. To fix this, a set of rules was created requiring scientists to check their books into a public digital catalog called "ClinicalTrials.gov" within a year of finishing their work. This catalog is supposed to be the master list where everyone can see the true results, good or bad, so that doctors can make the best decisions for their patients. But just because a rule exists doesn't mean everyone follows it perfectly.
This paper acts like a detective story, but instead of solving a crime, the authors are investigating how well scientists are following the rule to check their books into the catalog. They focused specifically on "hypertension," which is the medical term for high blood pressure—a condition that affects billions of people and is a major cause of heart trouble. The researchers wanted to know: Are the scientists actually putting their results in the catalog on time? And does it matter who is writing the book (like a big drug company versus a university) or what the book is about? They didn't just guess; they used a computer to scan thousands of records, looking for the specific moment a trial finished and counting how many days it took for the results to appear in the public record.
The investigation revealed a rather messy reality. Out of nearly 5,400 hypertension trials that were old enough to have reported their results, only about 9 out of every 100 (9.1%) actually submitted their results within the required 12-month window. That's like a library where 91% of the authors are late turning in their books. The paper suggests that the main reason a trial gets reported on time isn't because the scientists are naturally more responsible or because the disease is more important; it's because they are legally forced to do it.
The authors found a clear "obligation gradient." When a trial was clearly required by law to report (because it tested a new drug or device in the United States), the reporting rate jumped up to about 37% for on-time submissions. However, for the vast majority of trials that weren't strictly required to report—perhaps because they tested lifestyle changes or were done outside the US—the on-time reporting rate plummeted to just 6%. The study also noted that having a trial site in the United States was the strongest factor linked to timely reporting, far more than who was paying for the study.
Interestingly, the paper points out that while many trials eventually get reported (about 29% of all trials reported at some point), they often do so very late, missing the deadline that ensures the information is fresh for doctors. The authors also found that for the trials that never made it to the catalog, some had been published in scientific journals, but this doesn't solve the problem because journal articles are often harder to find and don't have the standardized data needed for quick medical decisions.
In short, the paper concludes that the system works best when there is a clear stick (a legal requirement) to make people act. When that stick is missing, even for a common and dangerous condition like high blood pressure, the results often stay hidden or arrive too late to be useful. The authors suggest that while the rules have helped the "flag-confirmed" trials, there is still a huge gap for the trials that fall outside the strict legal requirements, leaving a significant chunk of medical evidence out of reach for the doctors who need it most.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.